Abstract: medRxiv preprint doi: https://doi.org/10.1101/2022.04.21.22274060; this version posted April 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Effectiveness of the neutralizing antibody sotrovimab among highrisk patients with mild to moderate SARS-CoV-2 in Qatar Ahmed Zaqout,1,2* Muna A. Almaslamani,1,2 Hiam Chemaitelly,3,4,5 Samar A. Hashim,1,2 Ajithkumar Ittaman,1,2 Abeir Alimam,1,2 Fatma Rustom,1,6 Joanne Daghfal,1 Mohammed Abukhattab,1,2 Sawsan AlMukdad,3,4 Anvar Hassan Kaleeckal,7 Ali Nizar Latif, 7 Adeel A. Butt,2,5,10 Roberto Bertollini,8 Abdullatif Al-Khal,1,2 Ali S. Omrani,1,2 and Laith J. AbuRaddad3,4,5,9* 1 Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar 3 Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar 4 World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine–Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar 5 Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA 6 Pharmacy Department, Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar 7 Hamad Medical Corporation, Doha, Qatar 8 Ministry of Public Health, Doha, Qatar 9 Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar 10 Department of Medicine, Weill Cornell Medicine, New York, NY and Doha, Qatar 2 * Correspondence to Dr. Ahmed Zaqout, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar, e-mail: azaqout@hamad.qa Word count: Abstract: 50 words, Main Text: 1,499 words. Number of tables: 1. Running head: Real-world effectiveness of sotrovimab in Qatar. Keywords: COVID-19; SARS-CoV-2; sotrovimab, Omicron; BA.2; variant; subvariant; casecontrol; epidemiology. 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2022.04.21.22274060; this version posted April 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Abstract Effectiveness of sotrovimab against severe, critical, or fatal COVID-19 was investigated in Qatar using a case-control study design at a time when BA.2 Omicron subvariant dominated incidence. Adjusted odds ratio of progression to severe, critical, or fatal COVID-19, comparing those sotrovimab-treated to those untreated, was 2.67-fold higher (95% CI: 0.60-11.91). 2 medRxiv preprint doi: https://doi.org/10.1101/2022.04.21.22274060; this version posted April 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Several monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed for..